In order to examine the characteristics of the tumor and the blood flow to the liver, this stage entails comprehensive imaging such as CT or MRI. To find the arteries supplying the tumor and any aberrant blood vessel connections that could allow radioactive particles to enter non-target organs, an angiographic mapping is performed.
Sedation and local anesthesia are given. The femoral artery is used to introduce a catheter, which is then directed under fluoroscopy into the branches of the hepatic artery that supply the tumor. Precise targeting requires accurate location.
The catheter is used to gradually introduce yttrium-90 radioactive microspheres into the tumor-feeding arteries. By lodging in the tumor capillaries, the microspheres emit concentrated radiation that destroys tumor cells without harming healthy liver tissue.
Hemostasis is achieved at the access site by removing the catheter and applying pressure. The patient's acute side effects and problems are tracked. After one to three months, follow-up imaging is performed to evaluate tumor response and schedule additional therapy.
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
Patients with liver-dominant metastatic tumors that cannot be surgically removed or those with intermediate to advanced hepatocellular carcinoma (HCC) are the main candidates for this treatment.
Classified as Child-Pugh class A or early B, candidates usually have intact liver function, guaranteeing sufficient hepatic reserve.
Patients should be able to tolerate the surgery well if their ECOG performance level is between 0 and 2.
Yttrium-90 microspheres must be delivered selectively to the hepatic artery in order to target the tumor and spare healthy tissue.
When portal vein thrombosis is present, TARE is favored to TACE because it results in less ischemia.
It is appropriate for individuals who are waiting for a liver transplant to manage the growth of their tumors.
TARE is a minimally invasive procedure that uses a “pinhole” catheter method, which eliminates the need for open surgery and speeds up recovery.
By delivering strong radiation doses straight to the liver tumors, the yttrium-90 microspheres maximize tumor cell killing while protecting the surrounding healthy liver tissue.
Compared to some other local therapies, TARE achieves superior disease management and treatment response rates, which aid in tumor shrinkage and decrease disease progression.
Compared to transarterial chemoembolization (TACE), patients usually have less adverse effects, such as fever and abdominal pain.
Unlike embolization alone, TARE does not result in ischemia, making it safer and more effective for patients with portal vein invasion.
For improved therapeutic results, TARE can be successfully paired with other cancer treatments like chemotherapy or ablation.
It can be used as a bridge therapy while patients wait for a liver transplant or to downstage tumors.
After receiving TARE treatment, patients frequently report symptom reduction, enhanced quality of life, and extended overall survival.
702, 7th Floor, Solaris Kode, Near Khatu Shyam Temple, VIP Road, Vesu , Surat.
drjennygandhi98@gmail.com
+91 90033 03373
